DXRX vs. AGL, BVC, SCLP, EAH, POLB, SPEC, CEL, FARN, REDX, and ETX
Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), BATM Advanced Communications (BVC), Scancell (SCLP), ECO Animal Health Group (EAH), Poolbeg Pharma (POLB), INSPECS Group (SPEC), Celadon Pharmaceuticals (CEL), Faron Pharmaceuticals Oy (FARN), Redx Pharma (REDX), and e-therapeutics (ETX). These companies are all part of the "medical" sector.
Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Diaceutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.
Diaceutics has higher revenue and earnings than ANGLE.
ANGLE received 172 more outperform votes than Diaceutics when rated by MarketBeat users. However, 81.82% of users gave Diaceutics an outperform vote while only 62.20% of users gave ANGLE an outperform vote.
In the previous week, ANGLE had 2 more articles in the media than Diaceutics. MarketBeat recorded 2 mentions for ANGLE and 0 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.
Diaceutics has a net margin of 0.03% compared to ANGLE's net margin of 0.00%. Diaceutics' return on equity of 0.01% beat ANGLE's return on equity.
53.2% of Diaceutics shares are held by institutional investors. Comparatively, 27.2% of ANGLE shares are held by institutional investors. 34.5% of Diaceutics shares are held by company insiders. Comparatively, 10.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Diaceutics presently has a consensus price target of GBX 150, indicating a potential upside of 46.34%. ANGLE has a consensus price target of GBX 70, indicating a potential upside of 233.33%. Given ANGLE's higher probable upside, analysts plainly believe ANGLE is more favorable than Diaceutics.
Summary
Diaceutics beats ANGLE on 10 of the 14 factors compared between the two stocks.
Get Diaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Diaceutics Competitors List
Related Companies and Tools
